Redefining tau phosphorylation as a continuum of pathology in neurodegeneration rather than as a disease-specific marker could be achieved by extending this framework beyond AD and ALS to other tauopathies, such as Parkinson's disease (PD) and mixed dementias. The gene discussed is MAPT; the disease is Alzheimer disease.